Find the latest oncology news for your sub-specialty area
The latest results of a Phase II study evaluating the addition of venetoclax to the…
New four-year follow-up results from the Phase 3 GLOW study (Abstract #93), were announced during…
The targeted drug zanubrutinib showed superior efficacy with fewer side effects than ibrutinib in the…
The immunotherapy blinatumomab was found to improve overall survival for patients with no measurable residual…
In two separate studies, researchers demonstrate how synthetic biology can be used to tackle a difficult…
The Phase 3 MAIA study’s updated analyses reported progression-free survival, minimal residual disease negativity, overall…
Cancer, caused by abnormal overgrowth of cells, is the second-leading cause of death in the…
Researchers from the University of Bergen, Norway, have found a new method that within hours…
During the 64th annual meeting of the American Society of Hematology (ASH), held December 10-13…
Many children with ALL have a good outcome of their disease. After two years of chemotherapy…